Here, we report the therapeutic potential of BLD-2736, a novel inhibitor of calpain-1, 2, and 9 and cathepsin K, for the treatment of SCA3, following the detection of beneficial effects from treatment of SCA3 zebrafish larvae. This evidence concerns the gene CAPN1 and Spinocerebellar ataxia type 3.